Compare Cassava Sciences Inc (FLNA) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while State Street SPDR Bloomberg High Yield Bond ETF trades at $92.73 (market cap $5.86B). The key difference: State Street SPDR Bloomberg High Yield Bond ETF is far larger — about 148.7× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 7,780,002). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and State Street SPDR Bloomberg High Yield Bond ETF for 60 Days on average.
| FLNA | JNK | |
|---|---|---|
Market Cap | $39.40M | $5.86B |
Volume | 759,018 | 7,780,002 |
Sector | Health | Fixed Income |
52-Week High | $4.64 | $98.02 |
52-Week Low | $0.68 | $92.30 |
Typical Hold Time | 37 Days | 60 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
JNK trades at $92.695 with a slight 0.07% decline, showing technical bearish signals from moving averages while oscillators remain neutral. The ETF maintains consistent dividend distributions of $0.53 per share through mid-2026. Recent market focus centers on high-yield bond dynamics amid rising Treasury yields and institutional positioning changes.
The high-yield bond ETF faces headwinds from rising interest rates but benefits from institutional accumulation. Key risks include bond market volatility and economic sensitivity, while the consistent dividend stream provides income appeal for yield-seeking investors in the current rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
